查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1931207

藥物洗脫縫合線市場：按藥物類型、材料、應用、最終用戶和分銷管道分類，全球預測（2026-2032）

Drug Eluting Sutures Market by Drug Type, Material, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，藥物釋放型縫線市場價值將達到 15.4 億美元，到 2026 年將成長至 16 億美元，到 2032 年將達到 22.5 億美元，複合年成長率為 5.59%。

關鍵市場統計數據
基準年 2025 15.4億美元
預計年份：2026年 16億美元
預測年份 2032 22.5億美元
複合年成長率 (%) 5.59%

本書全面介紹了藥物釋放型縫線，闡述了其臨床原理、技術基礎以及在外科手術中的實際應用注意事項。

藥物釋放型縫合線透過將局部藥物治療直接整合到傷口縫合工具中，正在革新術後護理，從而減少全身治療的需求，並靶向組織修復關鍵連接點的生物反應。本文闡明了該技術的基本原理，並將其置於更廣泛的外科創新趨勢中，該趨勢優先考慮療效、患者安全和成本效益。透過將抗發炎、抗菌、抗粘連和促生長活性成分融入可吸收和不可吸收縫合線基質中，製造商旨在調節癒合動力學、降低感染率並改善多個外科專業的患者功能恢復。

深入分析融合的技術、監管和臨床變革如何重新定義縫合線作為局部治療遞送平台的作用

由於材料科學、藥理學、監管要求以及臨床對療效導向解決方案的需求等多方面因素的共同作用，藥物洗脫縫合線領域正經歷著變革性的轉變。聚合物化學和藥物包封技術的創新使得藥物釋放動力學更加穩定和可控，從而擴大了可安全整合到縫合線結構中的治療藥物種類。這使得臨床團隊逐漸將縫線視為局部藥物遞送平台，而不僅僅是機械閉合工具，能夠在一次手術中同時解決感染控制、發炎、沾黏和組織再生等問題。

對2025年關稅政策導致的供應鏈重組及其對採購定價和區域製造決策的策略影響進行詳細評估

2025年實施的新關稅迫使全球醫療設備供應鏈重組。這對藥物釋放型縫合線的影響尤其顯著，因為這類縫合線的原料、聚合物、活性藥物成分和成品在生產和分銷過程中往往需要跨越多個國界。某些聚合物和原料藥進口關稅的提高迫使製造商重新評估其籌資策略，在關稅優惠地區尋找替代供應商，並加快本土化和近岸化生產，以降低成本風險並維持利潤率。因此，先前奉行高度分散、成本最小化供應鏈模式的公司，如今正轉向評估總到岸成本和供應鏈韌性（除單位成本外）的模式。

將應用最終用戶、藥物劑型、材料選擇和分銷管道趨勢與商業化策略連結起來的綜合細分分析

了解細分市場的細微差別對於確定決定產品成功的臨床、商業性和生產優先事項至關重要。從應用角度分析市場，心血管外科（包括搭橋手術和瓣膜修復）是重點關注領域，因為感染和組織整合失敗的高風險促使臨床醫生尋求既能提供治療效果又能提供可預測機械支撐的材料。一般外科的應用案例涵蓋腹部手術、整形外科和泌尿系統，每種手術的組織動態和感染風險各不相同，因此需要客製化的縫合材料和藥物釋放特性。婦科、眼科和整形外科（整形外科分為關節重組和運動醫學）的應用案例表明，解剖位置和機械負荷如何決定材料選擇和藥物載量優先級。

跨區域策略分析重點闡述了美洲、歐洲、中東和非洲以及亞太地區監管和商業化差異對市場進入的影響。

區域趨勢對技術應用、監管路徑和商業模式產生了顯著影響，美洲、歐洲、中東和非洲以及亞太地區之間的戰略重點存在顯著差異。在美洲，大型醫院系統和專科手術中心正在推動臨床應用，強調以實證醫學為基礎的療效改進和成本控制。尖端材料和複雜醫療設備的臨床試驗投入也十分強勁，而報銷機制和採購週期則影響著新型縫線從試驗應用到廣泛應用的速度。

策略競爭概覽：平台創新、監管策略和供應鏈合作將如何決定藥物釋放型縫線領域的領導地位

藥物釋放型縫線領域的競爭格局呈現出多元化的特點，既有成熟的醫療設備製造商，也有專注於創新的專業企業，還有融合聚合物技術和製劑研發能力的多學科聯盟。主要企業正優先開發能夠承載多種藥物負荷並適配不同縫線材料的平台技術，以滿足各種外科手術需求。隨著市場參與者不斷調整自身定位，基於獨特的藥物遞送機制、檢驗的釋放動力學、易於手術操作、與滅菌工藝兼容以及大規模生產的可行性等差異化因素也逐漸顯現。

就產品開發、臨床證據、價值鏈韌性和商業化策略提出切實可行的建議，以推動產品應用和長期價值創造。

產業領導者應推動切實可行的舉措，整合產品創新、臨床證據和營運韌性。首先，應優先開發模組化平台，實現藥物有效載荷和基質的互換，從而支持多種適應症，並採用相同的生產和監管路徑。這種方法將加快新製劑的上市速度，並提高研發投資報酬率。其次，需要投資於嚴謹的、針對特定適應症的臨床項目，這些項目不僅要證明安全性，還要證明術後併發症的顯著減少和患者報告結局的改善。此類證據將有助於加強採購談判和與支付方的溝通。

我們採用了一種透明的調查方法，將臨床醫生採購和技術訪談與監管文獻和供應鏈分析相結合，以獲得可靠的見解。

本研究整合了質性訪談、文獻回顧和跨領域分析，以確保研究結果的嚴謹性和可重複性。主要資訊來源包括對心血管外科、一般外科、整形外科、婦科和眼科醫生的結構化訪談；對門診中心和醫院的採購和藥屋主管的訪談；以及對聚合物科學和藥物製劑專家的訪談。這些訪談旨在了解與藥物處理特性、臨床通訊協定和採購決策標準相關的實際考量，並由專家檢驗小組對訪談結果進行補充，以完善研究結論。

簡潔地總結了技術成熟度、監管和商業性因素，這些因素將決定藥物釋放型縫線的應用路徑。

對藥物釋放型縫合線的全面審視展現了這項技術的成熟。曾經的實驗性技術如今正被評估為一種能夠改善手術效果和病患體驗的實用工具。從心血管、整形外科到眼科，在各種應用領域，尖端材料、最佳化的載藥量以及專門開發的臨床證據的融合，正在重塑人們對縫合線在創傷治療過程中所能發揮的作用的預期。同時，關稅、地區監管差異以及不斷變化的採購重點等外部因素，仍持續影響這些產品的研發和應用方式及地點。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依藥物類型分類的藥物洗脫縫合線市場

  • 抗黏附藥物洗脫型
  • 抗發炎藥物釋放
    • 非類固醇消炎劑（NSAID）塗層
    • 類固醇塗層
  • 釋放抗生素
    • 銀塗層
    • 三氯生塗層
  • 生長因子釋放類型
    • BMP塗層
    • VEGF塗層

9. 藥物洗脫縫合線市場（依材料分類）

  • 自然的
    • 卡特加特
    • 絲綢
  • 合成
    • Poliglecaprone
    • 氧環己酮聚合體
    • Polyglactin

第10章 按應用分類的藥物洗脫縫合線市場

  • 心血管系統
    • 心臟繞道手術
    • 閥門維修
  • 一般外科
    • 腹部手術
    • 整形外科
    • 泌尿系統
  • 婦科
  • 眼科
  • 整形外科
    • 關節重組
    • 運動醫學

第11章 依最終用戶分類的藥物洗脫縫線市場

  • 門診手術中心
  • 診所
  • 醫院

12. 按分銷管道分類的藥物洗脫縫合線市場

  • 離線
  • 線上

13. 各地區藥物洗脫縫合線市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 藥物洗脫縫合線市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國藥物洗脫縫合線市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國藥物洗脫縫合線市場

第17章：中國藥物洗脫縫線市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aesculap AG
  • Allergan plc
  • AstraZeneca PLC
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Conmed Corporation
  • Cook Medical Incorporated
  • Ethicon, Inc.
  • GlaxoSmithKline plc
  • Integra LifeSciences Holdings Corporation
  • Johnson & Johnson
  • Kuros Biosciences AG
  • MicroPort Scientific Corporation
  • Novartis AG
  • Pfizer Inc.
  • Poly-Med, Inc.
  • Roche Holding AG
  • Smith & Nephew plc
  • Stryker Corporation
  • Synovis Micro Companies Alliance, Inc.
  • Teleflex Incorporated
  • Tepha, Inc.
  • Tigenix NV
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-7B550E008DBB

The Drug Eluting Sutures Market was valued at USD 1.54 billion in 2025 and is projected to grow to USD 1.60 billion in 2026, with a CAGR of 5.59%, reaching USD 2.25 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.54 billion
Estimated Year [2026] USD 1.60 billion
Forecast Year [2032] USD 2.25 billion
CAGR (%) 5.59%

Comprehensive introduction to drug eluting sutures explaining clinical rationale technological underpinnings and practical adoption considerations for surgical care

Drug eluting sutures are reshaping postoperative care by integrating localized pharmacotherapy directly into wound closure tools, which reduces the need for systemic treatments and targets biological responses at the critical interface of tissue repair. This introduction clarifies the technology premise while positioning the category within the broader continuum of surgical innovations that prioritize efficacy, patient safety, and cost-effective outcomes. By embedding active agents such as anti-inflammatory, antimicrobial, anti-adhesion, or growth-promoting compounds into absorbable and non-absorbable suture matrices, manufacturers aim to modulate healing kinetics, lower infection rates, and improve functional recovery across multiple surgical specialties.

As interest from surgeons, hospital procurement teams, and device innovators grows, the narrative around drug eluting sutures has shifted from proof-of-concept to pragmatic clinical integration. Early clinical data and device iterations emphasize predictable drug release profiles, biocompatible materials, and manufacturability at scale. Consequently, stakeholders are recalibrating clinical protocols, supply chain arrangements, and investment priorities to accommodate sutures that act as both closure devices and therapeutic delivery systems. In sum, the introduction contextualizes the technology's promise and delineates the practical considerations that are driving adoption and further innovation in surgical practice.

Detailed analysis of converging technological regulatory and clinical shifts redefining the role of sutures as localized therapeutic delivery platforms

The landscape for drug eluting sutures is experiencing transformative shifts driven by converging forces in materials science, pharmacology, regulatory expectations, and clinical demand for outcomes-based solutions. Innovations in polymer chemistry and drug encapsulation methods have enabled more consistent and tunable release kinetics, which in turn has expanded the range of therapeutic payloads that can be safely incorporated into suture constructs. As a result, clinical teams increasingly view sutures not just as mechanical closure tools but as local drug delivery platforms that can address infection control, inflammation, adhesions, and tissue regeneration within a single intervention.

Meanwhile, regulatory pathways are evolving to reflect the dual nature of these products, prompting manufacturers to align preclinical and clinical strategies with combination-product frameworks. This regulatory evolution is accompanied by heightened expectations for demonstrable patient benefit and safety, which has accelerated collaborations between device developers, pharmaceutical formulators, and clinical investigators. Concurrently, procurement strategies within hospitals and surgical centers are shifting toward value-based assessments that prioritize reductions in readmissions, complications, and total episode-of-care costs. Taken together, these shifts are creating a more sophisticated ecosystem in which technical differentiation, clinical evidence generation, and payer-aligned value propositions determine which technologies scale successfully from niche applications to broader surgical practice.

In-depth evaluation of the 2025 tariff-driven supply chain realignments and their strategic implications for sourcing pricing and regional manufacturing decisions

The implementation of new tariff measures in 2025 imposed a recalibration across global supply chains for medical devices, with distinct implications for the drug eluting sutures segment where raw materials, polymers, active pharmaceutical ingredients, and finished goods often cross multiple borders during manufacture and distribution. Heightened import duties on specific polymers and drug substances have compelled manufacturers to re-evaluate sourcing strategies, pursue alternative suppliers in tariff-favored jurisdictions, and accelerate onshoring or nearshoring efforts to mitigate cost exposure and preserve margin integrity. As a consequence, firms that had previously pursued highly fragmented, cost-minimizing supply chains are now modeling total landed cost and resilience alongside unit price.

In addition to procurement adaptations, the tariffs have affected pricing negotiations and contracting terms with end users. Hospitals and ambulatory centers are increasingly scrutinizing unit economics and seeking longer-term agreements that provide predictability against input-cost volatility. For some manufacturers, the tariff environment has encouraged vertical integration of certain value-chain activities such as polymer compounding or API finishing to reduce reliance on cross-border transactions. Moreover, the tariffs are accelerating strategic partnerships and localized manufacturing alliances in regions where trade policy is more favorable, thereby reshaping global commercial footprints and influencing where clinical trials, regulatory filings, and commercial launches are prioritized.

Comprehensive segmentation insights connecting application end user drug modality material selection and distribution channel dynamics to commercialization strategy

A nuanced understanding of segmentation is essential to identify the clinical, commercial, and manufacturing priorities that will determine product success. When the market is viewed through the lens of application, cardiovascular procedures, including bypass surgery and valve repair, represent a critical area of focus because the consequences of infection or impaired tissue integration are high and clinicians demand materials that deliver predictable mechanical support alongside therapeutic action. General surgery use cases span abdominal, plastic, and urological surgery, each with distinct tissue mechanics and infection risk profiles, which require tailored suture materials and drug release characteristics. Gynecology, ophthalmic, and orthopedic applications-where orthopedic further divides into joint reconstruction and sports medicine-illustrate how anatomical site and mechanical load drive material selection and drug payload priorities.

End users also shape clinical and procurement requirements in meaningful ways. Ambulatory surgical centers, which include both freestanding surgical centers and hospital-affiliated centers, prioritize streamlined logistics, cost containment, and procedural throughput; these priorities favor sutures that simplify perioperative protocols and reduce postoperative complications. Hospitals, differentiated into secondary care and tertiary care, concentrate on robustness of clinical evidence, interoperability with existing supply chains, and the capacity to support complex case mixes. From the perspective of drug type, the spectrum ranges from anti-adhesion eluting and anti-inflammatory eluting to antimicrobial eluting and growth factor eluting sutures, with subcategories such as NSAID-coated and steroid-coated for anti-inflammatory products, silver-coated and triclosan-coated antimicrobial variants, and BMP-coated and VEGF-coated growth factor sutures that address tissue regeneration. Material selection intersects with these therapeutic strategies; natural materials like catgut and silk offer distinct handling and resorption characteristics, while synthetic polymers such as poliglecaprone, polydioxanone, and polyglactin provide predictable degradation and mechanical profiles that can be engineered for controlled drug release.

Finally, distribution channel dynamics influence availability and adoption. Hospital pharmacies manage inpatient and outpatient needs with an emphasis on formulary inclusion and inventory control, whereas online pharmacies, whether through direct manufacturer channels or third-party vendors, expand accessibility and convenience. Retail pharmacies, including chain and independent outlets, serve ambulatory patients and often play a role in postoperative care continuity. Taken together, these intersecting segmentation dimensions underline the need for differentiated product development, tailored clinical evidence generation, and customized commercialization strategies that respect the distinct priorities of each application, end user, drug type, material, and distribution channel.

Cross-regional strategic analysis highlighting how adoption regulatory and commercial variations across the Americas Europe Middle East & Africa and Asia-Pacific inform market entry

Regional dynamics exert a strong influence on technology adoption, regulatory pathways, and commercial models, with important distinctions across the Americas, Europe, Middle East & Africa, and Asia-Pacific that shape strategic priorities. In the Americas, clinical adoption is driven by large hospital systems and specialized surgical centers that emphasize evidence-based improvements in outcomes and cost containment. This region also sees robust investment in advanced materials and combination-device trials, while reimbursement frameworks and procurement cycles influence how quickly novel sutures move from pilot use to broader adoption.

In Europe, Middle East & Africa, regulatory harmonization in parts of Europe contrasts with diverse regulatory and procurement environments across the Middle East and Africa, producing a mosaic of adoption timelines and commercialization approaches. Local manufacturing partnerships and distributor networks play a pivotal role in market entry strategies, and cross-border clinical collaborations often support evidence generation. In the Asia-Pacific region, rapid surgical volume growth and expansive ambulatory care networks create significant opportunities, while price sensitivity and a strong focus on scalable manufacturing lead organizations to pursue cost-effective material formulations and regional production hubs. Across all regions, differences in clinical practice patterns, hospital infrastructure, and payer priorities necessitate tailored go-to-market plans that align product design, evidence development, and supply chain configuration with local needs and regulatory expectations.

Strategic competitive overview describing how platform innovation regulatory strategy and supply chain partnerships determine leadership in the drug eluting sutures sector

Competitive dynamics in the drug eluting sutures arena are characterized by a mix of established medical device manufacturers, specialty innovators, and cross-disciplinary partnerships that combine polymer expertise with pharmaceutical formulation capabilities. Leading organizations are prioritizing platform technologies that can accommodate multiple drug payloads and be adapted for different suture materials to address a diverse set of surgical indications. As market actors position themselves, differentiation arises from proprietary drug-delivery mechanisms, validated release kinetics, ease of surgical handling, sterilization compatibility, and manufacturability at scale.

In addition to product differentiation, corporate strategies vary widely: some companies are investing heavily in clinical trials and regulatory filings to secure premium positioning in tertiary-care centers, while others focus on cost-effective production and channel partnerships to penetrate high-volume ambulatory settings and retail distribution. Strategic alliances between device makers and pharmaceutical or biotechnology firms have become more common, enabling accelerated formulation development and access to regulatory expertise for combination-product submissions. Furthermore, contract manufacturing organizations and specialized component suppliers play an essential role, as many innovators leverage external capabilities for scale-up, sterile processing, and quality systems compliance. These competitive patterns suggest that success will depend not only on clinical performance but also on supply chain reliability, regulatory acumen, and the ability to demonstrate compelling value propositions to diverse end users.

Actionable recommendations for product development clinical evidence supply chain resilience and commercialization strategies that drive adoption and long-term value

Industry leaders should pursue a set of actionable initiatives that align product innovation with clinical evidence and operational resilience. First, prioritize modular platform development that enables interchangeable drug payloads and material substrates so that the same manufacturing and regulatory pathways can support multiple indications. This approach reduces time-to-market for new formulations and improves return on development investment. Second, invest in rigorous, indication-specific clinical programs that demonstrate not only safety but also measurable reductions in postoperative complications and improvements in patient-reported outcomes; such evidence strengthens procurement conversations and payer engagement.

Third, fortify supply chain resilience by diversifying raw material suppliers, evaluating onshoring or nearshoring options where feasible, and securing long-term agreements that minimize exposure to tariff and logistics disruptions. Fourth, cultivate strategic partnerships with hospital systems, ambulatory surgical centers, and key pharmacy stakeholders to pilot usage protocols, facilitate formulary inclusion, and collect real-world evidence. Fifth, tailor commercialization strategies to regional dynamics by aligning pricing structures, regulatory submission sequences, and manufacturing footprints with local needs. Finally, embed health economics expertise early in product development to quantify value across the episode of care, enabling stronger conversations with payers and health system purchasers about the return on investment associated with adopting drug eluting suture technologies.

Transparent research methodology combining primary clinician procurement and technical interviews with secondary regulatory literature and supply chain analysis for robust insights

This research synthesizes primary qualitative interviews, secondary literature review, and cross-functional analysis to ensure rigorous and reproducible insights. Primary inputs include structured interviews with surgeons across cardiovascular general surgery orthopedic gynecology and ophthalmic specialties, procurement and pharmacy leaders in ambulatory centers and hospitals, and technical experts in polymer science and drug formulation. These interviews were designed to capture practical considerations related to handling characteristics clinical protocols, and procurement decision criteria, and they were augmented by expert validation panels to refine findings.

Secondary research incorporated peer-reviewed clinical studies, regulatory guidelines, standards for combination products, and publicly available filings that describe material properties and device classifications. In addition, supply chain assessments leveraged trade and logistics data to evaluate cost drivers, tariff exposure, and manufacturing footprints. Where possible, triangulation across primary and secondary sources was used to corroborate assertions about clinical preferences, material trade-offs, and regional regulatory dynamics. Analytical methods combined qualitative coding of interview data with scenario-based supply chain modeling and comparative regulatory pathway mapping to produce recommendations that are both evidence-informed and operationally actionable.

Concise conclusion synthesizing technological maturation regulatory and commercial considerations that determine the adoption trajectory for drug eluting sutures

The cumulative narrative around drug eluting sutures is one of maturation: technologies that once were experimental are increasingly being evaluated as pragmatic tools to improve surgical outcomes and patient experiences. Across applications from cardiovascular to orthopedic and ophthalmic care, the convergence of advanced materials, tailored drug payloads, and purpose-built clinical evidence is reshaping expectations for what sutures can accomplish during wound healing. At the same time, external forces such as tariffs, regional regulatory diversity, and evolving procurement priorities continue to influence how and where these products are developed and adopted.

In closing, stakeholders who integrate technical excellence with pragmatic commercialization strategies-grounded in robust evidence generation, resilient supply chains, and regionally appropriate go-to-market tactics-will be best positioned to realize the potential of drug eluting sutures. The path forward requires coordinated efforts across R&D, clinical affairs, regulatory, manufacturing, and commercial teams to ensure that product design aligns with real-world clinical needs and the complexities of global distribution and reimbursement environments.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Eluting Sutures Market, by Drug Type

  • 8.1. Anti-adhesion Eluting
  • 8.2. Anti-inflammatory Eluting
    • 8.2.1. Nsaid Coated
    • 8.2.2. Steroid Coated
  • 8.3. Antimicrobial Eluting
    • 8.3.1. Silver Coated
    • 8.3.2. Triclosan Coated
  • 8.4. Growth Factor Eluting
    • 8.4.1. Bmp Coated
    • 8.4.2. Vegf Coated

9. Drug Eluting Sutures Market, by Material

  • 9.1. Natural
    • 9.1.1. Catgut
    • 9.1.2. Silk
  • 9.2. Synthetic
    • 9.2.1. Poliglecaprone
    • 9.2.2. Polydioxanone
    • 9.2.3. Polyglactin

10. Drug Eluting Sutures Market, by Application

  • 10.1. Cardiovascular
    • 10.1.1. Bypass Surgery
    • 10.1.2. Valve Repair
  • 10.2. General Surgery
    • 10.2.1. Abdominal Surgery
    • 10.2.2. Plastic Surgery
    • 10.2.3. Urological Surgery
  • 10.3. Gynecology
  • 10.4. Ophthalmic
  • 10.5. Orthopedic
    • 10.5.1. Joint Reconstruction
    • 10.5.2. Sports Medicine

11. Drug Eluting Sutures Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Clinics
  • 11.3. Hospitals

12. Drug Eluting Sutures Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Drug Eluting Sutures Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Drug Eluting Sutures Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Drug Eluting Sutures Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Drug Eluting Sutures Market

17. China Drug Eluting Sutures Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Aesculap AG
  • 18.6. Allergan plc
  • 18.7. AstraZeneca PLC
  • 18.8. B. Braun Melsungen AG
  • 18.9. Becton, Dickinson and Company
  • 18.10. Conmed Corporation
  • 18.11. Cook Medical Incorporated
  • 18.12. Ethicon, Inc.
  • 18.13. GlaxoSmithKline plc
  • 18.14. Integra LifeSciences Holdings Corporation
  • 18.15. Johnson & Johnson
  • 18.16. Kuros Biosciences AG
  • 18.17. MicroPort Scientific Corporation
  • 18.18. Novartis AG
  • 18.19. Pfizer Inc.
  • 18.20. Poly-Med, Inc.
  • 18.21. Roche Holding AG
  • 18.22. Smith & Nephew plc
  • 18.23. Stryker Corporation
  • 18.24. Synovis Micro Companies Alliance, Inc.
  • 18.25. Teleflex Incorporated
  • 18.26. Tepha, Inc.
  • 18.27. Tigenix NV
  • 18.28. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG ELUTING SUTURES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUG ELUTING SUTURES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DRUG ELUTING SUTURES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DRUG ELUTING SUTURES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-ADHESION ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-ADHESION ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-ADHESION ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-INFLAMMATORY ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-INFLAMMATORY ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-INFLAMMATORY ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-INFLAMMATORY ELUTING, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY NSAID COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY NSAID COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY NSAID COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY STEROID COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY STEROID COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY STEROID COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY ANTIMICROBIAL ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY ANTIMICROBIAL ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY ANTIMICROBIAL ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY ANTIMICROBIAL ELUTING, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY SILVER COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY SILVER COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY SILVER COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY TRICLOSAN COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY TRICLOSAN COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY TRICLOSAN COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY GROWTH FACTOR ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY GROWTH FACTOR ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY GROWTH FACTOR ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY GROWTH FACTOR ELUTING, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY BMP COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY BMP COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY BMP COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY VEGF COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY VEGF COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY VEGF COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY NATURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY NATURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY NATURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY CATGUT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY CATGUT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY CATGUT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY SILK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY SILK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY SILK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY POLIGLECAPRONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY POLIGLECAPRONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY POLIGLECAPRONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY POLYDIOXANONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY POLYDIOXANONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY POLYDIOXANONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY POLYGLACTIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY POLYGLACTIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY POLYGLACTIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY BYPASS SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY BYPASS SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY BYPASS SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY VALVE REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY VALVE REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY VALVE REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY GENERAL SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY GENERAL SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY ABDOMINAL SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY ABDOMINAL SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY ABDOMINAL SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY PLASTIC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY PLASTIC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY PLASTIC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY UROLOGICAL SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY UROLOGICAL SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY UROLOGICAL SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY GYNECOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY GYNECOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY GYNECOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY OPHTHALMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY OPHTHALMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY OPHTHALMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY JOINT RECONSTRUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY JOINT RECONSTRUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY JOINT RECONSTRUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY SPORTS MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY SPORTS MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY SPORTS MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS DRUG ELUTING SUTURES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS DRUG ELUTING SUTURES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-INFLAMMATORY ELUTING, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS DRUG ELUTING SUTURES MARKET SIZE, BY ANTIMICROBIAL ELUTING, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS DRUG ELUTING SUTURES MARKET SIZE, BY GROWTH FACTOR ELUTING, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS DRUG ELUTING SUTURES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS DRUG ELUTING SUTURES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS DRUG ELUTING SUTURES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS DRUG ELUTING SUTURES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS DRUG ELUTING SUTURES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS DRUG ELUTING SUTURES MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS DRUG ELUTING SUTURES MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS DRUG ELUTING SUTURES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS DRUG ELUTING SUTURES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-INFLAMMATORY ELUTING, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY ANTIMICROBIAL ELUTING, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY GROWTH FACTOR ELUTING, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-INFLAMMATORY ELUTING, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY ANTIMICROBIAL ELUTING, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY GROWTH FACTOR ELUTING, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA DRUG ELUTING SUTURES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-INFLAMMATORY ELUTING, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY ANTIMICROBIAL ELUTING, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY GROWTH FACTOR ELUTING, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE DRUG ELUTING SUTURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE DRUG ELUTING SUTURES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-INFLAMMATORY ELUTING, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE DRUG ELUTING SUTURES MARKET SIZE, BY ANTIMICROBIAL ELUTING, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE DRUG ELUTING SUTURES MARKET SIZE, BY GROWTH FACTOR ELUTING, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE DRUG ELUTING SUTURES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE DRUG ELUTING SUTURES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE DRUG ELUTING SUTURES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE DRUG ELUTING SUTURES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE DRUG ELUTING SUTURES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE DRUG ELUTING SUTURES MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE DRUG ELUTING SUTURES MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE DRUG ELUTING SUTURES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE DRUG ELUTING SUTURES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST DRUG ELUTING SUTURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST DRUG ELUTING SUTURES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-INFLAMMATORY ELUTING, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST DRUG ELUTING SUTURES MARKET SIZE, BY ANTIMICROBIAL ELUTING, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST DRUG ELUTING SUTURES MARKET SIZE, BY GROWTH FACTOR ELUTING, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST DRUG ELUTING SUTURES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST DRUG ELUTING SUTURES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST DRUG ELUTING SUTURES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST DRUG ELUTING SUTURES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST DRUG ELUTING SUTURES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST DRUG ELUTING SUTURES MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST DRUG ELUTING SUTURES MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST DRUG ELUTING SUTURES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST DRUG ELUTING SUTURES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-INFLAMMATORY ELUTING, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY ANTIMICROBIAL ELUTING, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY GROWTH FACTOR ELUTING, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA DRUG ELUTING SUTURES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC DRUG ELUTING SUTURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC DRUG ELUTING SUTURES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-INFLAMMATORY ELUTING, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC DRUG ELUTING SUTURES MARKET SIZE, BY ANTIMICROBIAL ELUTING, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC DRUG ELUTING SUTURES MARKET SIZE, BY GROWTH FACTOR ELUTING, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC DRUG ELUTING SUTURES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC DRUG ELUTING SUTURES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC DRUG ELUTING SUTURES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC DRUG ELUTING SUTURES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC DRUG ELUTING SUTURES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC DRUG ELUTING SUTURES MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC DRUG ELUTING SUTURES MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC DRUG ELUTING SUTURES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC DRUG ELUTING SUTURES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN DRUG ELUTING SUTURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN DRUG ELUTING SUTURES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-INFLAMMATORY ELUTING, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN DRUG ELUTING SUTURES MARKET SIZE, BY ANTIMICROBIAL ELUTING, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN DRUG ELUTING SUTURES MARKET SIZE, BY GROWTH FACTOR ELUTING, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN DRUG ELUTING SUTURES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN DRUG ELUTING SUTURES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN DRUG ELUTING SUTURES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN DRUG ELUTING SUTURES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN DRUG ELUTING SUTURES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN DRUG ELUTING SUTURES MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN DRUG ELUTING SUTURES MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN DRUG ELUTING SUTURES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN DRUG ELUTING SUTURES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. GCC DRUG ELUTING SUTURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. GCC DRUG ELUTING SUTURES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. GCC DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-INFLAMMATORY ELUTING, 2018-2032 (USD MILLION)
  • TABLE 248. GCC DRUG ELUTING SUTURES MARKET SIZE, BY ANTIMICROBIAL ELUTING, 2018-2032 (USD MILLION)
  • TABLE 249. GCC DRUG ELUTING SUTURES MARKET SIZE, BY GROWTH FACTOR ELUTING, 2018-2032 (USD MILLION)
  • TABLE 250. GCC DRUG ELUTING SUTURES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 251. GCC DRUG ELUTING SUTURES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 252. GCC DRUG ELUTING SUTURES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 253. GCC DRUG ELUTING SUTURES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. GCC DRUG ELUTING SUTURES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 255. GCC DRUG ELUTING SUTURES MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 256. GCC DRUG ELUTING SUTURES MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 257. GCC DRUG ELUTING SUTURES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. GCC DRUG ELUTING SUTURES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION DRUG ELUTING SUTURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION DRUG ELUTING SUTURES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-INFLAMMATORY ELUTING, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION DRUG ELUTING SUTURES MARKET SIZE, BY ANTIMICROBIAL ELUTING, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION DRUG ELUTING SUTURES MARKET SIZE, BY GROWTH FACTOR ELUTING, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION DRUG ELUTING SUTURES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION DRUG ELUTING SUTURES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION DRUG ELUTING SUTURES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION DRUG ELUTING SUTURES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION DRUG ELUTING SUTURES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION DRUG ELUTING SUTURES MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION DRUG ELUTING SUTURES MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION DRUG ELUTING SUTURES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION DRUG ELUTING SUTURES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS DRUG ELUTING SUTURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS DRUG ELUTING SUTURES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-INFLAMMATORY ELUTING, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS DRUG ELUTING SUTURES MARKET SIZE, BY ANTIMICROBIAL ELUTING, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS DRUG ELUTING SUTURES MARKET SIZE, BY GROWTH FACTOR ELUTING, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS DRUG ELUTING SUTURES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS DRUG ELUTING SUTURES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS DRUG ELUTING SUTURES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS DRUG ELUTING SUTURES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS DRUG ELUTING SUTURES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS DRUG ELUTING SUTURES MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS DRUG ELUTING SUTURES MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS DRUG ELUTING SUTURES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS DRUG ELUTING SUTURES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. G7 DRUG ELUTING SUTURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 288. G7 DRUG ELUTING SUTURES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. G7 DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-INFLAMMATORY ELUTING, 2018-2032 (USD MILLION)
  • TABLE 290. G7 DRUG ELUTING SUTURES MARKET SIZE, BY ANTIMICROBIAL ELUTING, 2018-2032 (USD MILLION)
  • TABLE 291. G7 DRUG ELUTING SUTURES MARKET SIZE, BY GROWTH FACTOR ELUTING, 2018-2032 (USD MILLION)
  • TABLE 292. G7 DRUG ELUTING SUTURES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 293. G7 DRUG ELUTING SUTURES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 294. G7 DRUG ELUTING SUTURES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 295. G7 DRUG ELUTING SUTURES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 296. G7 DRUG ELUTING SUTURES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 297. G7 DRUG ELUTING SUTURES MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 298. G7 DRUG ELUTING SUTURES MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 299. G7 DRUG ELUTING SUTURES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. G7 DRUG ELUTING SUTURES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 301. NATO DRUG ELUTING SUTURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 302. NATO DRUG ELUTING SUTURES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. NATO DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-INFLAMMATORY ELUTING, 2018-2032 (USD MILLION)
  • TABLE 304. NATO DRUG ELUTING SUTURES MARKET SIZE, BY ANTIMICROBIAL ELUTING, 2018-2032 (USD MILLION)
  • TABLE 305. NATO DRUG ELUTING SUTURES MARKET SIZE, BY GROWTH FACTOR ELUTING, 2018-2032 (USD MILLION)
  • TABLE 306. NATO DRUG ELUTING SUTURES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 307. NATO DRUG ELUTING SUTURES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 308. NATO DRUG ELUTING SUTURES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 309. NATO DRUG ELUTING SUTURES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 310. NATO DRUG ELUTING SUTURES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 311. NATO DRUG ELUTING SUTURES MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 312. NATO DRUG ELUTING SUTURES MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 313. NATO DRUG ELUTING SUTURES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. NATO DRUG ELUTING SUTURES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 315. GLOBAL DRUG ELUTING SUTURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES DRUG ELUTING SUTURES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES DRUG ELUTING SUTURES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES DRUG ELUTING SUTURES MARKET SIZE, BY ANTI-INFLAMMATORY ELUTING, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES DRUG ELUTING SUTURES MARKET SIZE, BY ANTIMICROBIAL ELUTING, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES DRUG ELUTING SUTURES MARKET SIZE, BY GROWTH FACTOR ELUTING, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES DRUG ELUTING SUTURES MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES DRUG ELUTING SUTURES MARKET SIZE, BY NATURAL, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES DRUG ELUTING SUTURES MARKET SIZE, BY SYNTHETIC, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES DRUG ELUTING SUTURES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES DRUG ELUTING SUTURES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES DRUG ELUTING SUTURES MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES DRUG ELUTING SUTURES MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES DRUG ELUTING SUTURES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES DRUG ELUTING SUTURES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA DRUG ELUTING SUTURES MA